Management Team

Christopher Knowles, President and CEO

Christopher Knowles, Esq. joined TissueGen® in 2009 and has served as the company’s President and CEO since 2010. A licensed attorney, Christopher has represented corporate clients in diverse industries including nanotechnology, medicine, medical device, e-commerce, sports and entertainment, and government contracting. Prior to entering the private sector, Christopher served as a U.S. Air Force electronic warfare officer including combat and combat support operations in Europe, Iraq, and Afghanistan. Christopher entered military service upon graduation from the U.S. Air Force Academy with a Bachelor of Science and subsequently earned his Master of Business Administration at the University of Oklahoma and Juris Doctorate at Southern Methodist University.

Dr. Kevin D. Nelson, Founder and CSO

Kevin Nelson received his Ph.D. from The University of Texas Southwestern Medical Center at Dallas under the direction of Dr. Robert Eberhart. As a faculty member in Biomedical Engineering at the University of Texas at Arlington  in 1996, he joined a team working on an NIH grant to develop a fiber-based, biodegradable vascular stent with the goal of delivering gene therapy to the vessel wall. Simultaneously working with Dr. Nathan Schwade to develop drug-loaded microspheres for improved wound healing, he eventually combined the drug-loading techniques of microspheres with the fiber for the biodegradable stent, and fiber-based drug delivery was born. Eventually patented, this technology has been the focus of Dr. Nelson’s professional life and the driver behind TissueGen, Inc.

Dr. Brent Crow, Head, Special Programs

Brent B. Crow, Ph.D., joined TissueGen in 2006 as senior project scientist to lead the company’s research and development efforts and assumed the role of Head, Special Programs in 2016 to lead the company’s development of platform technologies for ELUTE fiber applications. Prior to his work at TissueGen, Brent served as chair of the Biomedical Engineering Technology department at DeVry University and held numerous engineering and logistics positions at Lockheed Martin, including work as a flight test technical specialist for the F-22 fighter program. Brent earned his Bachelor of Science in Aeronautical Engineering from Embry-Riddle Aeronautical University and Doctorate of Philosophy in Bioengineering from The University of Texas Southwestern Medical Center at Dallas /The University of Texas at Arlington Joint Program in Bioengineering. His doctoral work focused on tissue engineering, drug delivery, and biomaterials.

Dr. Jennifer Seifert, Director, Research and Development

Jennifer Seifert, Ph.D, joined TissueGen in 2015 as Senior Scientist to lead the company’s application of ELUTE fiber technology to treat spinal cord injuries and related applications for regenerative medicine and assumed responsibility as Director, Research and Development in 2016. Prior to joining TissueGen, Jennifer held the position of Research Assistant Professor in the Department of Bioengineering at University of Texas at Dallas. She has an extensive background in molecular biology and neuroscience and has focused her research career largely upon the development of repair strategies for the central and peripheral nervous systems applying cellular and molecular mechanisms of axonal growth. Jennifer holds a Ph.D. in molecular biology from Texas Woman’s University and Bachelor of Science in biology from the University of Texas at Dallas. She has received numerous honors, including being selected for the Chancellor’s Research Scholar Award in 2006, 2007, and 2008 and was awarded a grant from the Scoliosis Research Society for “Neuroprotection Against Oxidative Stress in an Animal Model of Distraction Spinal Cord Injury.”

Nickolas Griffin, Production Manager

Nickolas Griffin joined TissueGen in 2009 and has served as the company’s Production Manager since 2011. Nickolas was appointed interim quality control manager in late 2012 in preparation for the release of TissueGen’s first commercial product, ELUTE fiber. Nickolas earned his Bachelor of Science in Biomedical Engineering from Texas A&M and is a proud member of the Fighting Texas Aggie class of 2007.

Board of Directors

Kevin Cordell

Mr. Cordell currently serves as President, U.S. Extremities, for Wright Medical Technology, Inc.  Prior to joining Wright Medical, Mr. Cordell served as Vice President of Sales for the GI Solutions business at Covidien, a leading global healthcare products company, from May 2012 to September 2014. While at Covidien, he also served as Vice President of Sales & Global Marketing for its Peripheral Vascular business from July 2010 to May 2012. He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served as Vice President of U.S. Sales from January 2009 to July 2010. Prior to ev3, Mr. Cordell served as Vice President, Global Sales of FoxHollow Technologies, Inc. from March 2007 to October 2007. Earlier in his career, Mr. Cordell also held various positions of increasing responsibility for Johnson & Johnson’s Cordis Cardiology and Centocor companies.  Mr. Cordell received his Bachelor’s Degree in Finance from the University of Oklahoma.

James Dukowitz, Ph.D. (Chairman)

Dr. Dukowitz has more than 35 years of experience in high-tech industry, with particular strengths in the areas of strategic planning, business development, communications, international marketing and technology commercialization. At Texas Instruments, where he worked for more than 20 years, he served in senior executive positions including President of Texas Instruments Asia and President of Texas Instruments China. He also held several Vice Presidencies at Texas Instruments: corporate marketing, strategic planning, corporate relations, and corporate marketing communications. Upon retiring form TI in 1997, Dr. Dukowitz served as President of his own consulting practice advising early stage technology companies. He has served as a senior officer and member of the Board of Directors of several companies spanning biotechnology, semiconductors and educational services. As a Principal at Technology Innovation Group, he has been advising governments, NGOs and companies on matters of technology commercialization, commercial partnerships and business strategy. He also has governmental experience, serving on General Staff of the U.S. Army Security Agency Europe and as a senior program analyst in the Office of Secretary of Defense. He earned his Bachelor’s Degree in Mathematics from the University of Iowa and his Ph.D in Political Science with an emphasis on Science, Technology and Public Policy from the Massachusetts Institute of Technology. While at MIT he served as a special assistant to MIT President Jerome Wiesner in the formation of the Congressional Office of Technology assessment.

Jonathan Gibson

Mr. Gibson is the Chief Executive Officer and General Partner at Socratic Fund Management L.P., the firm he founded in 1997.  Mr. Gibson has extensive experience in the investment and energy industry and graduated from Lehigh University.

Christopher Knowles

Mr. Knowles joined TissueGen in 2009 and has served as the company’s President and CEO since 2010.  A licensed attorney, he has represented corporate clients in diverse industries including nanotechnology, medicine, medical device, e-commerce, sports and entertainment, and government contracting.  Prior to entering the private sector, Mr. Knowles served as a U.S. Air Force electronic warfare officer including combat and combat support operations in Europe, Iraq, and Afghanistan.  He entered military service upon graduation from the U.S. Air Force Academy with a Bachelor of Science and subsequently earned his Master of Business Administration at the University of Oklahoma and Juris Doctorate at Southern Methodist University.

Charles Munson

Mr. Munson is Manager and President of NCC Nano, LLC dba NovaCentrix and three additional companies involved in oil and gas production or minerals. He has over 25 years experience in energy markets and technologies including photovoltaics, and oil exploration and recovery. Mr. Munson graduated from Brown University with a dual degree in Geophysics and Math. The Munson family has been actively pursuing private equity investments for over a decade.

Kevin D. Nelson, Ph.D.

Dr. Nelson, TissueGen’s Founder and Chief Scientific Officer, received his Ph.D. from The University of Texas Southwestern Medical Center at Dallas under the direction of Dr. Robert Eberhart. As a faculty member in Biomedical Engineering at the University of Texas at Arlington in 1996, he joined a team working on an NIH grant to develop a fiber-based, bioresorbable vascular stent with the goal of delivering gene therapy to the vessel wall. Simultaneously working with Dr. Nathan Schwade to develop drug-loaded microspheres for improved wound healing, he eventually combined the drug-loading techniques of microspheres with the fiber for the bioresorbable stent, and fiber-based drug delivery was born. Now patented, this technology has been the focus of Dr. Nelson’s professional life and the driver behind TissueGen.

Richard W. Snyder II, MD, FACC

Dr. Snyder is a cardiologist at Medical City Dallas Hospital and board certified in Cardiovascular Disease, Interventional Cardiology, Advanced Heart Failure, and Transplant Cardiology.  He currently is a member of the Board of Trustees of the Texas Medical Association serving as Secretary, a Member of the Board of Directors for the North Texas Accountable Healthcare Partnership and a member of the North Texas Community Emergency Response Committee. Dr Snyder is also a member of the Dallas County Health and Human Services Public Health Advisory Committee and as well as a Vice President of HeartPlace and Cardiovascular Provider Resources.  Among other former positions, Dr. Snyder has served as President for not only the medical staff for Medical City Dallas Hospital, but also the Dallas County Medical Society, and the Texas Chapter of the American College of Cardiology. Additionally he was  a member of the Board of Governors for the American College of Cardiology in DC and as well as a Trustee of the Southwestern Medical Foundation.   After graduating from the University of Notre Dame, he completed medical school at the University of Texas Southwestern Medical School, with a residency in internal medicine and fellowship in cardiovascular disease.